Sotera Health (NASDAQ:SHC) Short Interest Update

Sotera Health (NASDAQ:SHC) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 6,610,000 shares, a drop of 18.7% from the November 30th total of 8,130,000 shares. Currently, 4.3% of the shares of the stock are sold short. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 5.2 days.

Sotera Health Trading Up 1.9 %

Shares of SHC traded up $0.26 during trading hours on Tuesday, reaching $13.62. The stock had a trading volume of 303,120 shares, compared to its average volume of 1,326,951. The company has a market cap of $3.86 billion, a P/E ratio of 54.48 and a beta of 1.96. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The firm has a 50-day moving average of $14.17 and a 200 day moving average of $14.29.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. During the same period in the prior year, the business earned $0.18 EPS. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, sell-side analysts expect that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on SHC shares. Citigroup upped their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. The Goldman Sachs Group started coverage on shares of Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Sotera Health has an average rating of “Moderate Buy” and an average target price of $16.08.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Darsana Capital Partners LP grew its holdings in shares of Sotera Health by 716.9% during the third quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock worth $334,167,000 after buying an additional 17,560,636 shares in the last quarter. Sessa Capital IM L.P. raised its holdings in shares of Sotera Health by 46.5% in the third quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock valued at $105,220,000 after purchasing an additional 2,000,000 shares during the last quarter. State Street Corp boosted its holdings in Sotera Health by 18.5% during the third quarter. State Street Corp now owns 4,126,806 shares of the company’s stock worth $68,918,000 after purchasing an additional 644,236 shares during the last quarter. AQR Capital Management LLC grew its position in Sotera Health by 3,198.2% in the second quarter. AQR Capital Management LLC now owns 511,580 shares of the company’s stock valued at $6,072,000 after purchasing an additional 496,069 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Sotera Health by 19.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after buying an additional 447,186 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.